

# Nutraceutical Use in Prostate Cancer

By Geo Espinosa, ND, LAc, IFMCP, CNS

## Complete References

1. Bray F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J. Clin.* 2018;68: 394–424.
2. <https://cancerstatisticscenter.cancer.org/#!/cancer-site/Prostate>
3. Zuniga KB, et al. Trends in Complementary and Alternative Medicine Use among Patients with Prostate Cancer. *J Urol.* 2019 May 15. 202:101097
4. Akhtar M, et al. Paget's "Seed and Soil" Theory of Cancer Metastasis: An Idea Whose Time has Come. *Adv Anat Pathol.* 2019 Jan;26(1):69-74.
5. Nguyen DP, et al. Recent insights into NF-kappaB signalling pathways and the link between inflammation and prostate cancer. *BJU Int.* 2014;114:168–176.
6. Udensi UK, Tchounwou PB. Oxidative stress in prostate hyperplasia and carcinogenesis. *J Exp Clin Cancer Res.* 2016; 35: 139.
7. Pasero C, et al. Highly effective NK cells are associated with good prognosis in patients with metastatic prostate cancer. *Oncotarget.* 2015;6(16):14360-14373.
8. Di Sebastiano KM, et al. Glucose impairments and insulin resistance in prostate cancer: the role of obesity, nutrition and exercise. *Obes Rev.* 2018 Jul;19(7):1008-1016.
9. Tosoian JJ, et al. Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer. *J Clin Oncol.* 2015 Aug 31.
10. Bill-Axelson A, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. *N Engl J Med.* 2011; 364:1708–1717.
11. Kumar RJ, Barqawi A, Crawford ED. Adverse events associated with hormonal therapy for prostate cancer. *Rev Urol.* 2005;7:S37–S43
12. de Bono JS, et al. Abiraterone and increased survival in metastatic prostate cancer. *N Engl J Med.* 2011 May 26. 364(21):1995-2005.
13. Clark LC, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. *JAMA.* 1996;276(24):1957-1963.
14. Lippman SM, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). *JAMA.* 2009;301(1):39-51.
15. Kristal AR, et al. Baseline selenium status and effects of selenium and vitamin E supplementation on prostate cancer risk. *J Natl Cancer Inst.* 2014;106
16. Nicastro H., Dunn BK. Selenium and prostate cancer prevention: Insights from the selenium and vitamin E cancer prevention trial (SELECT). *Nutrients*, 2013;5(4): 1122-1148.
17. Richie JP Jr, et al. Comparative effects of two different forms of selenium on oxidative stress biomarkers in healthy men: a randomized clinical trial. *Cancer Prev Res (Phila).* 2014 Aug;7(8):796-804.



18. Hartman TJ, et al. The association between baseline vitamin E, selenium, and prostate cancer in the alpha-tocopherol, beta-carotene cancer prevention study. *Cancer Epidemiol Biomarkers Prev.* 1998;7(4):335–40.
19. Wright ME, et al. Supplemental and dietary vitamin E intakes and risk of prostate cancer in a large prospective study. *Cancer Epidemiol Biomarkers Prev.* 2007;16(6):1128–35.
20. Virtamo J, et al. Effects of  $\alpha$ -tocopherol and  $\beta$ -carotene supplementation on cancer incidence and mortality: 18-year postintervention follow-up of the Alpha-tocopherol, Beta-carotene Cancer Prevention Study. *Int J Cancer.* 2014 Jul 1. 135(1):178-85
21. Helzlsouer KJ, et al. Association between  $\alpha$ -tocopherol,  $\gamma$ -tocopherol, selenium, and subsequent prostate cancer. *J Natl Cancer Inst.* 2000;92:2018–23.
22. Gonzalez A, et al. Zinc intake from supplements and diet and prostate cancer. *Nutr Cancer.* 2009;61(2):206-15.
23. Epstein MM, et al. Dietary zinc and prostate cancer survival in a Swedish cohort. *Am J Clin Nutr.* 2011; 93:586–593.
24. Leitzmann, MF, et al. Zinc supplement use and risk of prostate cancer. *Journal of the National Cancer Institute.* 2002; 95(13): 1004-1007.
25. Fang F, et al. Prediagnostic plasma vitamin D metabolites and mortality among patients with prostate cancer. *PLoS ONE.* 2011; 6: e18625.
26. Shahvazi S, et al. The Effect of Vitamin D Supplementation on Prostate Cancer: A Systematic Review and Meta-Analysis of Clinical Trials. *Horm Metab Res.* 2019 Jan;51(1):11-21.
27. Marshall DT, et al. Vitamin D3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance. *J Clin Endocrinol Metab.* 2012 Jul;97(7):2315-24.
28. Chandler PD, et al. Effect of Vitamin D3 Supplements on Development of Advanced Cancer: A Secondary Analysis of the VITAL Randomized Clinical Trial. *JAMA Network Open.*
29. Giordano A, Tommonaro G. Curcumin and Cancer. *Nutrients.* Oct 5, 2019;11:10 2376.
30. Hejazi J, et al. Effect of Curcumin Supplementation During Radiotherapy on Oxidative Status of Patients with Prostate Cancer: A Double Blinded, Randomized, Placebo-Controlled Study. *Nutr Cancer.* 2016;68(1):77-85.
31. Thomas R, et al. A double-blind, placebo-controlled randomised trial evaluating the effect of a polyphenol-rich whole food supplement on PSA progression in men with prostate cancer-the U.K. NCRN Pomi-T study. *Prostate Cancer Prostatic Dis.* 2014;17:180–186.
32. Agarwal C, Singh RP, Agarwal R. Grape seed extract induces apoptotic death of human prostate carcinoma DU145 cells via caspases activation accompanied by dissipation of mitochondrial membrane potential and cytochrome c release, *Carcinogenesis.* Nov 2002;23(11): 1869–1876.
33. Brasky TM, et al. Specialty supplements and prostate cancer risk in the VITamins and Lifestyle (VITAL) cohort. *Nutr Cancer.* 2011 May;63(4):573-82.
34. Zhang S, et al. Mushroom consumption and incident risk of prostate cancer in Japan: A pooled analysis of the Miyagi Cohort Study and the Ohsaki Cohort Study [published online September 3, 2019]. *Int J Cancer.*
35. Santesso N, Wieland LS. A Summary of a Cochrane Review: Ganoderma lucidum (Reishi mushroom) for the treatment of cancer. *Eur J Integr Med.* 2016;8(5):619-620.
36. Kuhara K, et al. CUB Domain-Containing Protein 1 (CDCP1) is down-regulated by active hexose-correlated compound in human pancreatic cancer cells. *Anticancer Res.* 2018;38:6107-6111.
37. Twardowski P, et al. A phase I trial of mushroom powder in patients with biochemically recurrent prostate cancer: Roles of cytokines and myeloid-derived suppressor cells for Agaricus bisporus-induced prostate-specific antigen responses. *Cancer.* 2015;121(17):2942-2950.
38. Chun JY, et al. Andrographolide, an herbal medicine, inhibits interleukin-6 expression and suppresses prostate cancer cell growth. *Genes Cancer.* 2010 Aug;1(8):868-76.

39. Lee, SO, et al. Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway. *Prostate*. 2004;60(3):178-86
40. Bettuzzi S, et al. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: A preliminary report from a one-year proof-of-principle study. *Cancer Res*. 2006;66(2): 1234-1240.
41. Zheng J, et al. Green tea and black tea consumption and prostate cancer risk: An exploratory meta-analysis of observational studies. *Nutr Cancer*. 2011;63(5): 663-672.
42. Jacob SA, Khan TM, Lee LH. The effect of green tea consumption on prostate cancer risk and progression: A systematic review. *Nutr Cancer*. 2017;69(3): 353-364.
43. Kumar NB, et al., Randomized, placebo-controlled trial of green tea catechins for prostate cancer prevention. *Cancer Prev Res*. 2015;8(10): 879-887.
44. Liu B, et al, Cruciferous vegetables intake and risk of prostate cancer: A meta-analysis. *Int J Urol*. 2012;19(2): 134-141.
45. Cipolla BG, et al, Effect of sulforaphane in men with biochemical recurrence after radical prostatectomy. *Cancer Prev Res*. 2015;8(8): 712-719.
46. Bosetti C, et al, Cruciferous vegetables and cancer risk in a network of case-control studies. *Ann Oncol*. 2012;23(8): 2198-2203.
47. Bradlow HL. Review. Indole-3-carbinol as a chemoprotective agent in breast and prostate cancer. *In Vivo* (Greece). July 1, 2008;22(4): 441-445.

